Pars Plana Vitrectomy (PPV) Versus Preoperative Intravitreal Bevacizumab Plus PPV to Treat Diabetic Tractional Retinal Detachment (IBETRA)

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the amount of intraoperative intraocular bleeding during 23-gauge pars plana vitrectomy (PPV) for diabetic traction retinal detachment (TRD) with and without preoperative intravitreal bevacizumab treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Sao Paulo
• Treatments: Bevacizumab; Temazepam

Criteria

Inclusion Criteria:

• Macular traction retinal detachment lasting three months or less secondary to diabetic retinopathy.

Exclusion Criteria:

• Massive vitreous hemorrhage preventing from detailed posterior pole examination;

• Previous intra-ocular surgery other than cataract surgery

• Hemodialysis, known bleeding disorders or use of anticoagulants drugs other than aspirin

• Prothrombin time, partial thromboplastin time or platelet count without normal limits

• History of previous thromboembolic events